Effect of Pentoxifylline on Preventing Chemotherapy-induced Toxicities in Patients With Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 25, 2023

Primary Completion Date

December 1, 2024

Study Completion Date

December 1, 2024

Conditions
Breast Cancer FemaleBreast Cancer PatientsNeoadjuvant TherapyDoxorubicinTaxane-induced Peripheral Neuropathy
Interventions
DRUG

Pentoxifylline 400mg plus chemotherapy

The patient will take 400 mg tablets of Pentoxifylline, 3 tablets per day, starting from the first day of the first cycle of doxorubicin/cyclophosphamide till finishing the cycles of neoadjuvant chemotherapy comprised intravenous Doxorubicin 60 mg/m²/cycle with intravenous cyclophosphamide 600 mg/m²/cycle for four cycles, followed by weekly paclitaxel, dose-dense paclitaxel or docetaxel.

DRUG

Chemotherapy

The patient will take chemotherapy cycle comprised intravenous Doxorubicin 60 mg/m²/cycle with intravenous Cyclophosphamide 600 mg/m²/cycle for four cycles, followed by weekly paclitaxel, dose-dense paclitaxel or docetaxel..

Trial Locations (1)

Unknown

Oncology Center of Mansoura University, Al Mansurah

All Listed Sponsors
lead

Mansoura University

OTHER

NCT06186700 - Effect of Pentoxifylline on Preventing Chemotherapy-induced Toxicities in Patients With Breast Cancer | Biotech Hunter | Biotech Hunter